Preserve Health
Protect Against Disease Prolong Healthspan
The Kitalys Institute promotes the translation of scientific advancements in healthy longevity into material, accessible improvements in public health.
RECENT NEWS
DIABETES TECHNOLOGY PROVIDES THE ROADMAP TO HEALTHY LONGEVITY
Kitalys Institute President and Co-Founder Alexander Fleming took the stage at the 26th Annual Diabetes Technology Meeting, outlining the intersection between diabetes technology and healthy longevity. Dr. Fleming explained how the principles of diabetes management could be applied to the individualized monitoring of biomarkers, producing produce earlier and longer windows for intervention in age-related disease.
ALEXANDER FLEMING RECEIVES DIABETES TECHNOLOGY LEADERSHIP AWARD
Kitalys Institute President and Co-Founder Alexander Fleming received the Diabetes Technology Society's annual Leadership Award! The award was presented at the 26th Annual Diabetes Technology Meeting in Washington, DC. Previous awardees include William Tamborlane, Viswanathan Mohan, and Alfred Mann.
PHOTOS FROM THE ASIA-PACIFIC HEALTHY LONGEVITY INTERNATIONAL SUMMIT
Follow us on LinkedIn for photos from the Asia-Pacific Healthy Longevity International Summit, which took place from October 1 through 4 in Hong Kong!
NOTABLE PROJECTS
OUR STORY
The Kitalys Institute is a not-for-profit created by Dr. Alexander Fleming. Dr. Fleming is founder and Executive Chair of Kinexum, a strategic advisory firm that provides regulatory consulting services for life science product development.
Dr. Fleming worked at the FDA from 1986 to 1998, where he oversaw therapies related to nutrition; disorders of growth, development, and reproduction; diabetes and its complications; and other metabolic and endocrine diseases. He led reviews of landmark approvals including metformin and the first statin, insulin analog, PPAR-agonist, and growth hormone for non-GH deficiency indications.
During his career, Dr. Fleming observed many barriers to the translation of breakthroughs into public health protocols, including: (i) the lack of a clear regulatory pathway for approval of therapeutic interventions; (ii) the need for clinical trials that are too large and last too long to attract funding to demonstrate prevention or delay of chronic diseases; and (iii) insufficient incentives for a payer to cover preventative interventions today that rather than paying for treatment years later.
Dr. Fleming re-imagined the regulatory system and scientific culture to safely increase the speed of scientific advances and make geroscience an integral part of public health. He believed that a not-for-profit organization could play a leading role in inspiring stakeholders to take the moonshot to increase healthy longevity for all. Therefore, in the spring of 2020, Kinexum formed the Kitalys Institute to organize conferences and other initiatives to turn emerging science into practical, equitable policy.